Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991334 | 1.00 | FFAR1 (0.56) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL21992015 | 1.00 | FFAR1 (0.56) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL21991319 | 0.91 | FFAR1 (0.50) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL21991857 | 0.90 | NPC1 (0.44) | FFAR1PPARGMAOB | |
| SCHEMBL21991365 | 0.90 | FFAR1 (0.55) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL21991562 | 0.88 | MAOB (0.57) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL21991563 | 0.87 | MAOB (0.56) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL21991566 | 0.87 | MAOB (0.51) | FFAR1PPARGMAOBMMEACE | |
| SCHEMBL23605727 | 0.87 | LMNA (0.55) | FFAR1MAOBLMNAL3MBTL1HRH3 | |
| SCHEMBL23605729 | 0.87 | LMNA (0.55) | FFAR1MAOBLMNAL3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | FFAR1 147/4885PPARG 1583/4885MAOB 3946/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | FFAR1 147/4885PPARG 1583/4885MAOB 3946/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | FFAR1 147/4885PPARG 1583/4885MAOB 3946/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | FFAR1 147/4885PPARG 1583/4885MAOB 3946/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | FFAR1 147/4885PPARG 1583/4885MAOB 3946/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | FFAR1 147/4885PPARG 1583/4885MAOB 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.